| 611 / 3SBio |
NCT06173284: Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 510 | RoW | 611, Matching placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic | 09/25 | 05/26 | | |
NCT06554847: Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 400 | RoW | 611, Placebo, Topical corticosteroid | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic, Eczema, Atopic | 10/25 | 08/26 | | |
NCT06639295: A Study to Evaluate 611 in Patients with Chronic Rhinosinusitis with Nasal Polyps |
|
|
| Not yet recruiting | 3 | 240 | RoW | 611, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Sinusitis, Nasal Polyps | 12/25 | 08/26 | | |
| Completed | 2 | 93 | RoW | 611 Q2W, 611 Q4W, Matching placebo, placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic | 07/23 | 09/23 | | |
NCT05865496: A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Active, not recruiting | 2 | 90 | RoW | 611, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Sinusitis, Nasal Polyps, Polyps | 05/24 | 07/24 | | |
NCT06099652: Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 2 | 150 | RoW | 611 300 mg Q2W, 611 450 mg Q2W, Matching placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Pulmonary Disease, Chronic Obstructive | 04/25 | 05/25 | | |
NCT06324812: Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 1/2 | 104 | NA | Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic | 08/24 | 08/24 | | |
